2-[(7-But-2-ynyl-2-methoxy-8-oxo-6-piperazin-1-ylpurin-9-yl)methyl]benzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[(7-But-2-ynyl-2-methoxy-8-oxo-6-piperazin-1-ylpurin-9-yl)methyl]benzonitrile
• 化学式: C₂₂H₂₃N₇O₂
• 分子量: 417.5
• InChiKey: CRFKIRPQCSBNKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  97.6
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES
  申请人：Akolkar Nakul Pramod

  公开号：US20120040897A1

  公开（公告）日：2012-02-16

  A compound of formula (I) or a tautomeric form, regioisomer, stereoisomer, solvate, N-oxide or pharmaceutically acceptable salts thereof; wherein ‘a’—is selected from the group consisting of substituted or unsubstituted heterocycloalkyl ring and substituted or unsubstituted carbohydrate moiety y is a member selected from —O—, —CO—, —S02-, aminoalkyl or formula (II) wherein, R w is hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; x is a member selected from -0-, —S—, —SO—, —S02-, CONR10, NR10CO and —NR d —, or x and y together represent a chemical bond; Z is selected from —CH—, —N—. t is an integer selected from O to 4; with the provisos that when ‘a’ is substituted or unsubstituted heterocycloalkyl ring then ‘t’ is not O and when y=—CO—, x is not NR d .

  化合物的公式（I）或其互变异构体，区域异构体，立体异构体，溶剂化物，N-氧化物或其药学上可接受的盐；其中，‘a’选择自取代或未取代的杂环烷基环或取代或未取代的碳水化合物基团，y为成员选择自—O—，—CO—，—S02-，氨基烷基或公式（II）其中，Rw为氢，取代或未取代的烷基，烯基，炔基，环烷基，芳基，杂环芳基；x为成员选择自-0-，—S—，—SO—，—S02-，CONR10，NR10CO和—NRd—，或x和y一起表示化学键；Z选择自—CH—，—N—。 t为整数，选择自0到4；条件是当‘a’为取代或未取代的杂环烷基环时，‘t’不为0，当y=—CO—时，x不为NRd。
• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Schilling Stephan

  公开号：US20090018087A1

  公开（公告）日：2009-01-15

  The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
• US7304086B2
  申请人：——

  公开号：US7304086B2

  公开（公告）日：2007-12-04
• US7524847B2
  申请人：——

  公开号：US7524847B2

  公开（公告）日：2009-04-28
• US7897633B2
  申请人：——

  公开号：US7897633B2

  公开（公告）日：2011-03-01